Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2019
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms The RIFF study
- Sponsors Chugai Pharmaceutical; Roche
- 14 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.
- 23 May 2018 Primary endpoint (Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks : Cohort A) has not been met.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society